Jolene Shorr

1.2k total citations
23 papers, 889 citations indexed

About

Jolene Shorr is a scholar working on Genetics, Genetics and Oncology. According to data from OpenAlex, Jolene Shorr has authored 23 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 6 papers in Genetics and 4 papers in Oncology. Recurrent topics in Jolene Shorr's work include Virus-based gene therapy research (6 papers), Cancer Research and Treatments (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Jolene Shorr is often cited by papers focused on Virus-based gene therapy research (6 papers), Cancer Research and Treatments (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Jolene Shorr collaborates with scholars based in United States, United Kingdom and Switzerland. Jolene Shorr's co-authors include Jason Gotlib, Ayalew Tefferi, Catriona Jamieson, Animesh Pardanani, Michael H. Silverman, Richard M. Stone, Jörge E. Cortes, Moshe Talpaz, Bettina J. Steffen and Russell H. Wiesner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jolene Shorr

21 papers receiving 861 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jolene Shorr United States 10 318 225 216 189 133 23 889
Nils Albiin Sweden 21 58 0.2× 138 0.6× 102 0.5× 188 1.0× 320 2.4× 48 1.2k
John R. Glossop United Kingdom 16 104 0.3× 79 0.4× 281 1.3× 38 0.2× 75 0.6× 22 737
M.B. Bradley United States 21 155 0.5× 498 2.2× 137 0.6× 16 0.1× 117 0.9× 44 1.3k
Mark D. Jäger Germany 18 51 0.2× 61 0.3× 113 0.5× 134 0.7× 305 2.3× 46 803
Cedric Francois United States 19 183 0.6× 256 1.1× 84 0.4× 33 0.2× 307 2.3× 43 1.2k
F Grossi United States 15 186 0.6× 259 1.2× 57 0.3× 35 0.2× 140 1.1× 48 998
Loukia S. Poulou Greece 12 50 0.2× 74 0.3× 26 0.1× 188 1.0× 157 1.2× 28 680
Weiyan Zheng China 14 113 0.4× 351 1.6× 240 1.1× 13 0.1× 53 0.4× 71 800
Karl-Walter Jauch Germany 17 235 0.7× 22 0.1× 254 1.2× 45 0.2× 221 1.7× 20 936
Fumiaki Sugiura Japan 13 130 0.4× 109 0.5× 161 0.7× 17 0.1× 100 0.8× 25 730

Countries citing papers authored by Jolene Shorr

Since Specialization
Citations

This map shows the geographic impact of Jolene Shorr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jolene Shorr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jolene Shorr more than expected).

Fields of papers citing papers by Jolene Shorr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jolene Shorr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jolene Shorr. The network helps show where Jolene Shorr may publish in the future.

Co-authorship network of co-authors of Jolene Shorr

This figure shows the co-authorship network connecting the top 25 collaborators of Jolene Shorr. A scholar is included among the top collaborators of Jolene Shorr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jolene Shorr. Jolene Shorr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Merchan, Jaime R., Jordi Rodon, Shree Venkat, et al.. (2025). A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects. Molecular Therapy. 33(11). 5505–5515.
2.
3.
Falchook, Gerald S., Jordi Rodón, Shree Venkat, et al.. (2020). Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.. Journal of Clinical Oncology. 38(4_suppl). 186–186. 4 indexed citations
4.
Merchan, Jaime R., Jordi Rodón, Gerald S. Falchook, et al.. (2018). Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.. Journal of Clinical Oncology. 36(15_suppl). TPS2613–TPS2613. 1 indexed citations
5.
Merchan, Jaime R., et al.. (2018). Toca 511 and Toca FC in patients with gastrointestinal tumors in the Toca 6 study.. Journal of Clinical Oncology. 36(4_suppl). TPS880–TPS880.
6.
Inagaki, Akihito, Angela M. Richardson, Sara Collins, et al.. (2017). TMOD-15. TOCA 511 & TOCA FC: PRE-CLINICAL PROOF OF CONCEPT IN CNS METASTATIC BREAST CANCER. Neuro-Oncology. 19(suppl_6). vi257–vi257. 1 indexed citations
7.
Cloughesy, Timothy F., Tobias Walbert, Daniela A. Bota, et al.. (2016). ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG). Neuro-Oncology. 18(suppl_6). vi17–vi17. 2 indexed citations
8.
Pardanani, Animesh, Jason Gotlib, Catriona Jamieson, et al.. (2011). Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology. 29(7). 789–796. 310 indexed citations
9.
Pardanani, Animesh, Jason Gotlib, Catriona Jamieson, et al.. (2010). Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2V617F Allele Burden. Blood. 116(21). 459–459. 8 indexed citations
10.
Pardanani, Animesh, Jason Gotlib, Catriona Jamieson, et al.. (2009). A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.. Blood. 114(22). 755–755. 32 indexed citations
11.
Lasho, Terra L., et al.. (2008). TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, Potently Inhibits KITD816V and FIP1L1-PDGFRA in Vitro. Blood. 112(11). 2807–2807. 1 indexed citations
12.
Lake, John R., Jolene Shorr, Bettina J. Steffen, et al.. (2005). Differential Effects of Donor Age in Liver Transplant Recipients Infected With Hepatitis B, Hepatitis C and Without Viral Hepatitis. American Journal of Transplantation. 5(3). 549–557. 130 indexed citations
13.
Wiesner, Russell H., Jolene Shorr, Bettina J. Steffen, et al.. (2005). Mycophenolate mofetil combination therapy improves long‐term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transplantation. 11(7). 750–759. 87 indexed citations
14.
Hirst, Peter H., Gary R. Pitcairn, Thomas E. Tarara, et al.. (2002). In Vivo Lung Deposition of Hollow Porous Particles from a Pressurized Metered Dose Inhaler. Pharmaceutical Research. 19(3). 258–264. 68 indexed citations
15.
Noveck, Robert J., et al.. (2000). Randomized Safety Studies of Intravenous Perflubron Emulsion. I. Effects on Coagulation Function in Healthy Volunteers. Anesthesia & Analgesia. 91(4). 804–811. 49 indexed citations
16.
Noveck, Robert J., Emer Shannon, Jolene Shorr, et al.. (2000). Randomized Safety Studies of Intravenous Perflubron Emulsion. II. Effects on Immune Function in Healthy Volunteers. Anesthesia & Analgesia. 91(4). 812–822. 74 indexed citations
17.
Bisset, George S., et al.. (1996). Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population. Pediatric Radiology. 26(6). 409–415. 8 indexed citations
18.
Shorr, Jolene, et al.. (1994). Preclinical and Clinical Studies on Lymph Node Imaging Using Perflubron Emulsion. Artificial Cells Blood Substitutes and Biotechnology. 22(4). 1429–1439. 4 indexed citations
19.
Shorr, Jolene, Dean C. Delis, & Paul J. Massman. (1992). Memory for the Rey-Osterrieth Figure: Perceptual clustering, encoding, and storage.. Neuropsychology. 6(1). 43–50. 14 indexed citations
20.
Shorr, Jolene, Dean C. Delis, & Paul J. Massman. (1992). Memory for the Rey-Osterrieth Figure: Perceptual clustering, encoding, and storage.. Neuropsychology. 6(1). 43–50. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nils Albiin Breakdown of academic impact, for papers by John R. Glossop Breakdown of academic impact, for papers by M.B. Bradley Breakdown of academic impact, for papers by Mark D. Jäger Breakdown of academic impact, for papers by Cedric Francois Breakdown of academic impact, for papers by F Grossi Breakdown of academic impact, for papers by Loukia S. Poulou Breakdown of academic impact, for papers by Weiyan Zheng Breakdown of academic impact, for papers by Karl-Walter Jauch Breakdown of academic impact, for papers by Fumiaki Sugiura
Rankless by CCL
2026